Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314262 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00314262 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 17 participants.
The verdict
NCT00314262, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Evaluate effect on cells and patient response to study medications, assess side effects of these medications, and evaluate chemicals in cells that may tell how the drug works, before, and after receiving the study medications.
Interventions
- DRUG Erlotinib & Celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2006-10 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00314262
The ClinicalTrials.gov registry entry for NCT00314262 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erlotinib & Celecoxib is the first listed.
NCT00314262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00314262 about?
NCT00314262 is a clinical study titled "Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor". Evaluate effect on cells and patient response to study medications, assess side effects of these medications, and evaluate chemicals in cells that may tell how the drug works, before, and after receiving the study medications.
What is the current status of trial NCT00314262?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2006-10. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00314262?
The interventions under investigation include: Erlotinib & Celecoxib (DRUG).
Who is sponsoring clinical trial NCT00314262?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.